Status:
COMPLETED
A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring
Lead Sponsor:
Pfizer
Conditions:
Urinary Bladder, Overactive
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare the difference between tolterodine prolonged release (PR) and propiverine in efficacy as assessed by the AUM and to show that tolterodine PR is similar to propi...
Eligibility Criteria
Inclusion
- Symptoms of urinary urgency
- Symptoms of urinary frequency (greater than or equal to 8 micturitions per 24 hours) as verified on the patient's micturition chart
- Symptoms of overactive bladder for greater than or equal to 6 months
Exclusion
- Stress incontinence as determined by the investigator and confirmed for female patients by a cough provocation test
- An average volume voided of \>200 ml per micturition as verified on the micturition chart before randomization
- Total daily urine volume of \>3000 ml as verified on the micturition chart before randomization
Key Trial Info
Start Date :
March 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2003
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT00646880
Start Date
March 1 2003
End Date
August 1 2003
Last Update
March 31 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Seoul, South Korea, 110-744